Deposition and disposition of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomography

Clinical Pharmacokinetics

Volumn 36, Issue SUPPL. 1, 1999, Pages 33-39

  Bergstrom, Mats ^a   Cass, Lindsey M R ^b   Valind, Sven ^a   Westerberg, Goran ^a   Lundberg, Eva Lise ^a   Gray, Steven ^b   Bye, Alan ^b   Langstrom, Bengt ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ZANAMIVIR; CARBON; GUANIDINE DERIVATIVE; PYRAN DERIVATIVE; SIALIC ACID DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; ESOPHAGUS; HUMAN; HUMAN EXPERIMENT; INTRANASAL DRUG ADMINISTRATION; LOWER RESPIRATORY TRACT; MALE; NOSE CAVITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STOMACH; BLOOD; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG SCREENING; METABOLISM; PHARYNX; REFERENCE VALUE; SCINTISCANNING;

ADMINISTRATION, INTRANASAL; ADULT; ANTIVIRAL AGENTS; CARBON RADIOISOTOPES; DRUG EVALUATION; ESOPHAGUS; GUANIDINES; HUMANS; MALE; PHARYNX; PYRANS; REFERENCE VALUES; SIALIC ACIDS; STOMACH; TOMOGRAPHY, EMISSION-COMPUTED; ZANAMIVIR;

EID: 0032993862     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199936001-00004     Document Type: Article

References (16)

1. 1. Von Itzstein M, Wu W-Y, Kok GB, et al. Rational design of potent sialidase based inhibitors of influenza virus replication. Nature 1993: 363: 418-23
2. 2. Whittington A, Bethell R. Recent developments in the antiviral therapy of influenza. Expert Opin Ther Patents 1995; 5: 793-803
3. 3. Woods JM, Bethell RC, Coates JAV, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993; 37: 1473-9
4. 4. Hayden FG, Lobo M, Hussey EK, et al. Efficacy of intranasal GGI67 in experimental human influenza A and B virus infection. Int Cngr Ser (1996), 1123. Options for the control of Influenza III: 718-25
5. 4. Hayden FG, Lobo M, Hussey EK, et al. Efficacy of intranasal GGI67 in experimental human influenza A and B virus infection. Int Cngr Ser (1996), 1123. Options for the control of Influenza III: 718-25
6. 5. Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GGI67 in experimental human influenza. JAMA 1996; 275: 295-9
7. 6. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337: 874-80
8. 7. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis. In press
9. 8. Matsumoto K, Nerome K, Numasaki Y, et al. Inhaled and intranasal GGI67 in the treatment of influenza A and B: preliminary results. Int Cngr Ser (1996), 1123. Options for the Control of Influenza III: 713-71
10. 8. Matsumoto K, Nerome K, Numasaki Y, et al. Inhaled and intranasal GGI67 in the treatment of influenza A and B: preliminary results. Int Cngr Ser (1996), 1123. Options for the Control of Influenza III: 713-71
11. 9. Kops ER, Herzog H, Schmid A, et al. Performance characteristics ol an eight ring whole body PET scanner. J Comput Assist Tomogr 1990; 14: 437-45
12. 11C]zanamivir) - an influenza virus neuraminidase inhibitor. J Label Compounds Radiopharm 1996; 38: 585-9
13. 11C]cyanogen bromide. Appl Radiat Isot 1997; 48: 459-61
14. 11C-nicotine vapour in the human airway as visu alized by positron emission tomography. Clin Pharmacol Ther 1995; 57: 309-17
15. 13. Lunell E, Bergstrom M, Antoni G, et al. Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with position emission tomography. Clin Pharm Ther 1996; 13: 593-4
16. 14. Cass LMR, Efthymiopoulos C, Bye A. Pharamcokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999; 36 Suppl. 1: 1-11